Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Güner Akgüner has a total of 138 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The Role of Dominant Lesion Site and SUVmax in the Depth of PSA Response in Metastatic Hormone-Sensitive Prostate Cancer

    by Güner Akgüner, Ayşegül İlhan Güleşen, Özgen Ahmet Yıldırım

    Background/Objectives: Depth of prostate-specific antigen (PSA) response is prognostic in metastatic hormone-sensitive prostate cancer (mHSPC), and the SUVmax of the most avid lesion is a readily available parameter on staging PSMA PET/CT. Uptake intensity and the anatomical site of that lesion are, however, distinct features. This study evaluated their associations with the depth of PSA response. Methods: In this retrospective single-centre study of men receiving androgen deprivation therapy plus an androgen receptor pathway inhibitor (ARPI), the SUVmax and anatomical site of the dominant lesion were derived from baseline 68Ga-PSMA-11 PET/CT. The primary outcome was a PSA nadir < 0.2 ng/mL, analysed using logistic regression with sequential adjustment and within strata defined by disease burden. Progression-free survival (PFS) was a secondary outcome. Results: Among 100 men with evaluable baseline PET/CT, SUVmax was associated with neither PSA response depth nor PFS in any parameterisation examined. A deep PSA response was achieved by 72%, 52% and 29% of patients with prostate-, node- and bone-dominant disease (trend p < 0.001), with median nadirs of 0.08, 0.19 and 0.50 ng/mL. Among patients with bone metastases, a deep response occurred in 29% with bone-dominant disease and 57% with a dominant lesion elsewhere (p = 0.016). The association persisted across sequentially adjusted models (OR range 0.22–0.33) and within high-volume disease (p = 0.008). Under a six-month landmark, deep PSA response was associated with longer PFS (HR 0.10, 95% CI 0.01–0.42), whereas bone dominance was not. Conclusions: The site of the dominant PSMA PET/CT lesion, but not its SUVmax, was associated with the depth of PSA response in ARPI-treated mHSPC. These findings require prospective validation.

  • Open Access

    Prognostic and Treatment-Context Associations of EASIX and IPI in Extensive-Stage Small-Cell Lung Cancer Patients Receiving First-Line Therapy

    by Hatice Ayyıldız Sevim, Galip Can Uyar, Güner Akgüner, Hayriye Şahinli

    Background: The comparative prognostic value of the Endothelial Activation and Stress Index (EASIX) and the Inflammatory Prognostic Index (IPI) in extensive-stage small-cell lung cancer remains unclear. This study aimed to compare the prognostic value of EASIX and IPI and assess their contribution beyond established clinical factors. Methods: This retrospective single-center study included 129 patients with de novo extensive-stage small-cell lung cancer who initiated first-line systemic therapy between December 2022 and October 2025. Pretreatment EASIX and IPI values were analyzed as log2-transformed continuous variables in multivariable Cox models. Overall survival was the primary outcome, and first-line progression-free survival was the secondary outcome. Results: During a median follow-up of 26.91 months, 116 deaths and 123 progression-or-death events occurred. Each doubling of the EASIX value was independently associated with a higher hazard of death (adjusted hazard ratio, 1.14; 95% confidence interval, 1.01–1.28; p = 0.019), whereas IPI was not independently associated with overall survival. Neither index was independently associated with first-line progression-free survival. Adding EASIX to the clinical model improved model fit and increased the C-index from 0.619 to 0.650, whereas IPI provided no additional prognostic contribution. Conclusions: EASIX may provide prognostic information beyond established clinical factors for overall survival in extensive-stage small-cell lung cancer. These findings warrant validation in larger multicenter cohorts.

  • Open Access

    Claudin 18.2 Positivity Thresholds and Candidate Populations for Targeted Therapy in Pancreatic Ductal Adenocarcinoma: A Real-World Retrospective Cohort

    by Güner Akgüner, Elif Haznedaroğlu Benlioğlu, Özgen Ahmet Yıldırım, Ayşegül İlhan Güleşen, Batuhan Günel, Ata Türker Arıkök, Ömür Berna Çakmak Öksüzoğlu, Kadriye Bir Yücel

    Background/Objectives: Claudin 18.2 (CLDN18.2) is expressed in a substantial proportion of pancreatic ductal adenocarcinoma (PDAC) and has emerged as a promising therapeutic target. However, the positivity threshold for enrollment in CLDN18.2-directed trials remains undefined, and ongoing studies use different criteria. We quantified how different CLDN18.2 thresholds influence the size of the candidate population within the same PDAC cohort. Methods: In this retrospective single-center study, CLDN18.2 was assessed by immunohistochemistry (43-14A clone, Ventana BenchMark) in 99 PDAC patients (metastatic, n = 71; non-metastatic, n = 28). The candidate population was evaluated at three thresholds: two used in current CLDN18.2 trials (any-intensity [1+/2+/3+] staining in ≥40% and moderate-to-strong [2+/3+] staining in ≥75% of tumor cells) and an exploratory lower bound of any detectable expression (≥5%). Between-threshold reclassification was analyzed as paired data; clinicopathological and survival analyses were exploratory. Results: The candidate proportion was 40.4% (40/99) at ≥75%, 43.4% (43/99) at ≥40%, and 64.6% (64/99) at ≥5%; among metastatic patients, it was 36.6%, 38.0%, and 59.2%, respectively. Lowering the threshold from ≥75% to ≥40% caused virtually no reclassification (1/71 metastatic, 1.4%; McNemar p = 1.0), whereas lowering it to ≥5% reclassified 16 metastatic patients (22.5%; 95% CI, 14.4–33.5; p < 0.001) as candidates. Among the 64 tumors with detectable expression, median staining was 80% (IQR, 20–90%). Survival analyses were exploratory and underpowered (52 deaths; 80% power for HR ≥ 2.24); no association between CLDN18.2 and overall or progression-free survival was detected at any threshold. Conclusions: The stringent thresholds used in current drug development identified nearly identical candidate populations, whereas relaxation to any detectable expression substantially enlarged the pool; CLDN18.2 behaved as a targetable rather than a prognostic biomarker. Our findings highlight the need for a PDAC-specific, response-based CLDN18.2 threshold.

  • Open Access

    Association Between Treatment-Emergent Pancreatic Volume Loss and Survival Outcomes in Patients with Metastatic Colorectal Cancer Receiving Bevacizumab

    by Hatice Ayyıldız Sevim, Hayriye Şahinli, Galip Can Uyar, Selahattin Çelik, Salih Karatlı, Güner Akgüner, Berna Turhan, Sümeyya Duran Kaymak, Rasime Pelin Kavak, Gökşen İnanç İmamoğlu

    Background and Objectives: The effect of bevacizumab on the morphology of non-tumoral organs remains unclear. We evaluated computed tomography (CT)- derived treatment-emergent pancreatic volume loss and examined its association with progression-free survival (PFS) and overall survival (OS) in patients with metastatic colorectal cancer receiving bevacizumab. Materials and Methods: This single-center retrospective study included 105 patients treated at Ankara Etlik City Hospital who had evaluable paired contrast-enhanced CT scans obtained before and during therapy. Pancreatic volume was measured on CT, and percentage volume loss was calculated. Clinical, laboratory, radiological, and survival data were retrospectively reviewed. Results: Mean pancreatic volume declined from 89.9 ± 6.1 mL before treatment to 83.6 ± 5.1 mL during therapy (p < 0.001). Albumin levels and platelet counts also decreased, whereas amylase, hemoglobin, and the neutrophil-to-lymphocyte ratio remained largely unchanged. In the main multivariable models, each 1% increase in pancreatic volume loss was associated with worse bevacizumab-line PFS (HR 1.06, 95% CI 1.02–1.10; p = 0.032) and OS (HR 1.08, 95% CI 1.01–1.15; p = 0.041). Percentage change in albumin was independently associated with both endpoints. Sensitivity analyses supported a more consistent association of pancreatic volume loss with PFS than with OS. Conclusions: Pancreatic volume decreased during bevacizumab-containing therapy. Greater pancreatic volume loss was associated with shorter PFS and OS; however, the association was more consistent for PFS. Prospective studies are needed to validate these findings and determine their clinical relevance.

  • Granülosit koloni stimülan faktörün yaygın evre küçük hücreli akciğer kanserinde etkinlik ve güvenilirliğinin retrospektif analizi

    by Güner Akgüner, Galip Can Uyar, Kadriye Başkurt, Osman Sütçüoğlu

    Amaç: Yaygın evre küçük hücreli akciğer kanseri (ES-SCLC), kötü prognozlu olup tedavisinde platin bazlı kemoterapi temel yaklaşımdır. Kemoterapinin yol açtığı nötropeni, febril nötropeni nedeniyle tedavi gecikmelerine ve hastaneye yatışlara neden olabilir. Granülosit koloni uyarıcı faktör (G-CSF) kullanımı, kemoterapiye bağlı nötropeni ve febril nötropeni insidansını azaltmaktadır. Bu çalışmanın amacı, ES-SCLC'de G-CSF kullanımının prognoz üzerindeki etkisini ve güvenilirliğini değerlendirmektir. Gereç ve Yöntemler: Bu tek merkezli, retrospektif çalışmaya 80 hasta dahil edilmiştir. Hastalar G-CSF kullanımına göre sınıflandırılmış ve genel sağkalım (OS) ile progresyonsuz sağkalım (PFS) gruplar arasında karşılaştırılmıştır. Prognoza etki eden faktörleri belirlemek amacıyla Cox regresyon modeli kullanılarak tek değişkenli ve çok değişkenli analizler yapılmıştır. G-CSF kullanımının güvenilirliği de değerlendirilmiştir. Bulgular: G-CSF grubunda medyan genel sağkalım (OS) 11,0 ay, G-CSF kullanılmayan grupta 8,6 aydı (p = 0,026). Medyan progresyonsuz sağkalım (PFS) G-CSF grubunda 8,0 ay, G-CSF kullanılmayan grupta 7,0 aydı (p = 0,044). Primer profilaksi grubunda medyan OS 15,1 ay, sekonder profilaksi grubunda ise 10,2 aydı (p = 0,099). Medyan PFS primer profilaksi grubunda 10,0 ay, sekonder profilaksi grubunda 7,4 aydı (p = 0,014). Multivariate analizde G-CSF kullanımı, daha uzun genel sağkalım (OS) (HR: 0,51; %95 CI: 0,28–0,90, p = 0,021) ve progresyonsuz sağkalım (PFS) (HR:0,57, %95 CI: 0,34-0,95, p = 0,031) için bağımsız bir prognostik faktör olarak tanımlandı. G-CSF kullanımına bağlı olarak 69 hastada (%86.3) herhangi bir advers olay gözlenmeyip, sadece 1 hastada (%1,3) ciddi (Grade 3) advers olay (trombositopeni) saptandı. Sonuç: Bu çalışmada, yaygın evre küçük hücreli akciğer kanseri (ES-SCLC) hastalarında G-CSF kullanımının genel sağkalımı iyileştirdiği bulunmuştur. Bu bulguları desteklemek için daha geniş ölçekli prospektif çalışmalara ihtiyaç duyulmaktadır.

  • The Impact of Systemic Inflammation and Nutritional Indicators on Progression-Free Survival in Patients with Metastatic Clear Cell Renal Carcinoma Receiving First-Line Tyrosine Kinase Inhibitor Therapy

    by Galip Can Uyar, Güner Akgüner, Kadriye Başkurt, Enes Yeşilbaş, Seher Kaya, Gökşen İnAnç İmAmoğlu

    Background: Systemic inflammation and nutritional status are key determinants of prognosis in metastatic clear-cell renal carcinoma (mccRCC). Composite indices such as the Systemic Immune–Inflammation Index (SII) and the Modified Glasgow Prognostic Score (mGPS) have demonstrated prognostic relevance across cancers, but real-world data in mccRCC remain limited. Methods: This retrospective, single-center cohort included patients with histologically confirmed mccRCC who received first-line tyrosine kinase inhibitor (TKI) monotherapy (sunitinib, pazopanib, or cabozantinib) between November 2022 and November 2024 at Etlik City Hospital (Ankara, Türkiye). Associations between inflammatory–nutritional indices (SII, mGPS) and progression-free survival (PFS) were evaluated using Kaplan–Meier and multivariable logistic regression analyses. Results: A total of 55 patients met eligibility criteria and were included in the analysis. The median age was 62 years (IQR 52–71), and 67% were male. Median PFS was 13.24 months (95% CI 7.75–19.12), while median OS was not reached. High SII (≥ 870) was independently associated with shorter PFS in multivariable analysis (OR 5.05; 95% CI 1.14–15.77; p = 0.039). mGPS (1–2) was significantly associated with inferior PFS in Kaplan–Meier analysis (HR 3.43; 95% CI 1.42–8.30; p = 0.006; log-rank p = 0.001), but lost significance in multivariable modeling. Metformin use (OR 0.12; 95% CI 0.02–0.93; p = 0.044), sunitinib therapy (OR 0.07; 95% CI 0.006–0.74; p = 0.027), and favorable/intermediate IMDC risk group (OR 0.17; 95% CI 0.06–0.96; p = 0.047) were independently associated with a lower progression risk. Patients treated with cabozantinib (n = 15) showed a numerically longer median PFS (18.6 months; 95% CI 13.8–23.3) compared with sunitinib (n = 25, 12.2 months; 95% CI 5.5–19.0) and pazopanib (n = 15, 12.1 months; 95% CI 6.7–17.5), although this difference was not statistically significant (log-rank p = 0.152). Conclusion: In this real-world cohort of patients with mccRCC treated with first-line TKI, host-related inflammatory and nutritional status were closely associated with progression-free survival. Additionally, patients classified within the favorable IMDC risk group exhibited a significantly lower risk of progression, highlighting the importance of integrating clinical risk stratification with systemic inflammatory and nutritional markers. Incorporating such easily measurable biomarkers and clinical risk scores into existing prognostic models may enhance individualized risk assessment and therapeutic decision-making. Future prospective, multicenter, randomized controlled, and artificial intelligence–assisted studies are warranted to validate these findings and refine precision oncology approaches in this population.


  • Top Cited Papers
    Open Access

    Prognostic utility of the C-reactive protein–albumin–lymphocyte (CALLY) index in metastatic renal cell carcinoma

    by Güner Akgüner, Mustafa Altınbaş

    Background and objective: The CALLY index has been recognized as a prognostic biomarker across various malignancies; however, its prognostic utility in metastatic renal cell carcinoma (mRCC) has not been extensively characterized. This study aimed to elucidate the prognostic significance of the C-reactive protein–albumin–lymphocyte (CALLY) index in patients diagnosed with mRCC. Methods: In this retrospective multicenter study, patients with metastatic renal cell carcinoma were included. Demographic and disease-related data were collected. The CALLY index was calculated as follows: serum albumin level (g/dL) × absolute lymphocyte count (cells/µL)/C-reactive protein (CRP) (mg/dL) × 104. The optimal cut-off value for the CALLY index was determined using maximal log-rank analysis. Overall survival and progression-free survival analyses were performed according to the cut-off value, and Cox regression analyses were conducted to identify factors affecting prognosis. Results: A total of 95 patients were included in the present study. The prognostic cut-off value for the CALLY index was determined as 0.12. The median overall survival (OS) was 11.1 months (95% CI 6.7–15.4) in the CALLY index < 0.12 group, compared to 45.7 months (95% CI 31.6–59.8) in the CALLY index ≥ 0.12 group (p < 0.001). Similarly, the median progression-free survival (PFS) was 7.1 months (95% CI 4.5–13.2) in the CALLY index < 0.12 group and 33.1 months (95% CI 17.2–48.1) in the CALLY index ≥ 0.12 group (p < 0.001). In Cox regression analysis, a CALLY index < 0.12 was identified as an independent prognostic factor for shorter OS (HR: 0.41, 95% CI 0.22–0.76, p = 0.004) and PFS (HR: 0.40, 95% CI 0.23–0.69, p = 0.001). Conclusion: The CALLY index was identified as an independent prognostic biomarker in metastatic renal cell carcinoma. Prospective large-scale studies are needed to confirm its clinical utility.


  • Kaposi Sarkomu

    by Güner Akgüner

    Kaposi Sarkomu (KS) endotel hücrelerinin multifokal malignitesi olup Kaposi Sarkomu ilişkili Herpesvirüs’le sıkı bir ilişkisi mevcuttur. AIDS ilişkili, endemik, klasik ve iyatrojenik ya da transplantasyon ilişkili dört tipi vardır. HIV(+) hastalarda HIV enfeksiyonunun yönetimi KS tedavisinde önemlidir. Lokal tedaviler, kemoterapi, immünoterapi gibi sistemik tedaviler, radyoterapi tedavide kullanılmaktadır. Hastaların takibinde anamnez, detaylı fizik muayene, laboratuvar testleri önemli olup, sistemik hastalık, progresif/refrakter hastalık varlığında takiplerde ek olarak radyolojik görüntüleme yöntemleri (X-RAY, BT, MRI, PET-BT) de kullanılmaktadır. HIV(+) vakalarda HIV tedavisinin yönetimi ve takibi KS tedavisinde önemlidir. Kaposi Sarcoma (KS) is a multifocal malignancy of endothelial cells and is strongly associated with Kaposi's Sarcoma-associated Herpesvirus (KSHV). There are four types of KS: AIDS-related, endemic, classic, and iatrogenic or transplant-associated. In HIV-positive patients, the management of HIV infection plays a critical role in the treatment of KS. Treatment modalities include local therapies, chemotherapy, immunotherapy, and radiotherapy. During patient follow-up, taking a detailed medical history, conducting thorough physical examinations, and performing laboratory tests are crucial. Additionally, in the presence of systemic or progressive/refractory disease, radiological imaging methods such as X-ray, CT, MRI, and PET-CT are also utilized. The management and monitoring of HIV treatment are essential components in the management of KS in HIV-positive patients.

  • Open Access

    Kanserde Takip

    by Şermin Dinç Sonuşen, İbRahim Bilen, Ömer Faruk Kuzu, Özden Demir, Hülya Odabaşı Bükün, Harun Muğlu, Abdülkadir Koçanoğlu, Pınar Çoban Eşdur, Ayberk Bayramgil, Orçun Can, et al.